HomeEXECUTIVES

EXECUTIVES

Nusano Names Medical Radioisotopes Advisory Board

“As a radioisotope producer, Nusano plays a critical role in the supply chains of drug developers, healthcare providers and researchers,” said Chris Lowe, CEO of Nusano. “Establishing a Medical Radioisotopes Advisory Board reflects our ongoing commitment to proactively enabling the next generation of oncology research. The board’s guidance will ensure Nusano is providing a stable and scalable supply of isotopes for new areas of research and patient care.”

Jason Whiting Appointed CEO of Avation Medical

Jason Whiting has more than 25 years of experience in the MedTech industry, driving innovation and adoption of new technologies in the implantable, capital equipment, and wearable markets.

Jay Hallinan Appointed Chief Commercial Officer of Q’Apel Medical

Jay Hallinan will lead the company's global sales and marketing organization, oversee Q'Apel's commercial strategy and drive revenue growth across Q'Apel's expanding product portfolio.

Robert Guigley Is Appointed Chief Commercial Officer of DELFI Diagnostics

Robert Guigley most recently served as the Chief Commercial Officer at Invitae, where he orchestrated a commercial reorganization to transition from a growth-centric to a sustainable profit model.

Darrin T Schellin Becomes the New CEO at Pharma Tech Industries

Pharma Tech Industries, a leading global provider of contract manufacturing and packaging solutions for pharmaceutical, medical device, and wellness products, has announced the immediate...

Mark Gaffney Is Appointed CEO of Calluna Pharma | Mark Altmeyer as Independent Chair of the Board

Mark Gaffney brings over 20 years of experience in corporate strategy, business development, and operations in both private and public biotechnology companies, and will lead the team that defines and executes on the corporate strategy, particularly as its lead program is on pace to complete its Phase 1 program later this year. 

John Beeler Appointed SVP of Business Development at BPGbio

Dr. John Beeler is a seasoned biopharma executive with extensive experience in growing innovative companies, will lead BPGbio’s business development team in securing licensing and commercial partnership opportunities for BPGbio’s NAi Interrogative Biology platform and its extensive pipeline of AI-developed therapeutic candidates.

Christopher Whitmore Appointed CFO at Ray Therapeutics

Christopher Whitmore is a highly accomplished executive who brings over 20 years of strategic finance, accounting, and operational expertise. His deep experience spans from early-stage biotech to publicly-traded companies, with a focus on both private and public capital raising.

Andy Fuller Appointed VP of Market Access at AESAR

With over 27 years of experience in the pharmaceutical industry, Andy Fuller brings extensive expertise in developing and executing go-to-market and payer engagement strategies across highly competitive markets.
Exit mobile version